Patents by Inventor Harald Johan Ruijssenaars
Harald Johan Ruijssenaars has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11034979Abstract: The invention relates to fungal cells for the production of FDCA. The fungal cell is genetically modified to have at least one of a) a genetic modification that confers to or increases in the cell the ability to oxidize 5-hydroxymethyl-2-furancarboxylic acid to 5-formyl-2-furoic acid; and, b) a genetic modification that reduces catabolism of 2,5-furandicarboxylic acid in the cell. The fungal cell can further be genetically modified to increase the cell's ability to oxidize furanic aldehydes to the corresponding furanic carboxylic acids. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) wherein the cells of the invention are used for oxidation of a furanic precursors of FDCA.Type: GrantFiled: September 21, 2016Date of Patent: June 15, 2021Assignee: Purac Biochem B.V.Inventors: Johannes Adrianus Maria de Bont, Harald Johan Ruijssenaars, Jan Werij
-
Publication number: 20200102584Abstract: The invention relates to fungal cells for the production of FDCA. The fungal cell has genetic modification that reduces specific 2,5-furandicarboxylic acid (FDCA) decarboxylating monooxygenase activity in the cell, as compared to a corresponding parent cell lacking the genetic modification. The fungal cell can further be genetically modified to increase the cell's ability to oxidize furanic aldehydes to the corresponding furanic carboxylic acids. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) wherein the cells of the invention are used for oxidation of a furanic precursors of FDCA to FDCA.Type: ApplicationFiled: March 21, 2018Publication date: April 2, 2020Applicant: Purac Biochem B.V.Inventors: Johannes Adrianus Maria de Bont, Harald Johan Ruijssenaars, Jan Werij
-
Patent number: 10457965Abstract: The invention relates to a cell expressing a polypeptide having 5-hydroxymethyl-2-furancarboxylic acid dehydrogenase activity, as well as to a cell expressing a polypeptide having furanic compound transport capabilities. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) wherein the cells of the invention are used for oxidation of a furanic precursors of FDCA.Type: GrantFiled: February 17, 2016Date of Patent: October 29, 2019Assignee: PURAC BIOCHEM B.V.Inventor: Harald Johan Ruijssenaars
-
Publication number: 20180265896Abstract: The invention relates to fungal cells for the production of FDCA. The fungal cell is genetically modified to have at least one of a) a genetic modification that confers to or increases in the cell the ability to oxidize 5-hydroxymethyl-2-furancarboxylic acid to 5-formyl-2-furoic acid; and, b) a genetic modification that reduces catabolism of 2,5-furandicarboxylic acid in the cell. The fungal cell can further be genetically modified to increase the cell's ability to oxidize furanic aldehydes to the corresponding furanic carboxylic acids. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) wherein the cells of the invention are used for oxidation of a furanic precursors of FDCA.Type: ApplicationFiled: September 21, 2016Publication date: September 20, 2018Applicant: Purac Biochem B.V.Inventors: Johannes Adrianus Maria de Bont, Harald Johan Ruijssenaars, Jan Werij
-
Patent number: 10023890Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: GrantFiled: August 25, 2017Date of Patent: July 17, 2018Assignee: Purac Biochem B.V.Inventors: Nick Johannes Petrus Wierckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Publication number: 20180030488Abstract: The invention relates to a cell expressing a polypeptide having 5-hydroxymethyl-2-furancarboxylic acid dehydrogenase activity, as well as to a cell expressing a polypeptide having furanic compound transport capabilities. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) wherein the cells of the invention are used for oxidation of a furanic precursors of FDCA.Type: ApplicationFiled: February 17, 2016Publication date: February 1, 2018Applicant: Purac Biochem B.V.Inventor: Harald Johan RUIJSSENAARS
-
Publication number: 20180023105Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: ApplicationFiled: August 25, 2017Publication date: January 25, 2018Inventors: Nick Johannes Petrus Wierckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Patent number: 9828616Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: GrantFiled: March 3, 2016Date of Patent: November 28, 2017Assignee: Purac Biochem B.V.Inventors: Nick Johannes Petrus Wierckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Patent number: 9481900Abstract: The invention relates to a polypeptide having oxidoreductase activity which comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having 45% or more sequence identity with the sequence of SEQ ID NO: 3. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) or production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid).Type: GrantFiled: April 3, 2015Date of Patent: November 1, 2016Assignee: Purac Biochem B.V.Inventors: Harald Johan Ruijssenaars, Nick Johannes Petrus Wierckx, Frank Wouter Koopman, Adrianus Johannes Jozef Straathof, Johannes Hendrik De Winde
-
Publication number: 20160257978Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: ApplicationFiled: March 3, 2016Publication date: September 8, 2016Inventors: Nick Johannes Petrus Wierckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Patent number: 9309546Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: GrantFiled: March 7, 2012Date of Patent: April 12, 2016Assignee: Purac Biochem B.V.Inventors: Nick Johannes Petrus Wierckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Publication number: 20150203882Abstract: The invention relates to a polypeptide having oxidoreductase activity which comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having 45% or more sequence identity with the sequence of SEQ ID NO: 3. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) or production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid).Type: ApplicationFiled: April 3, 2015Publication date: July 23, 2015Applicant: Purac Biochem B.V.Inventors: Harald Johan RUIJSSENAARS, Nick Johannes Petrus Wierckx, Frank Wouter Koopman, Adrianus Johannes Jozef Straathof, Johannes Hendrik De Winde
-
Patent number: 9045787Abstract: The invention relates to a polypeptide having oxidoreductase activity which comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having 45% or more sequence identity with the sequence of SEQ ID NO: 3. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) or production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid).Type: GrantFiled: September 2, 2010Date of Patent: June 2, 2015Assignee: Purac Biochem B.V.Inventors: Harald Johan Ruijssenaars, Nick Johannes Petrus Wierckx, Frank Wouter Koopman, Adrianus Johannes Jozef Straathof, Johannes Hendrik De Winde
-
Publication number: 20140073019Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: ApplicationFiled: March 7, 2012Publication date: March 13, 2014Applicant: PURAC BIOCHEM B.V.Inventors: Nick Johannes Petrus Werckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Publication number: 20120309918Abstract: The invention relates to a polypeptide having oxidoreductase activity which comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having 45% or more sequence identity with the sequence of SEQ ID NO: 3. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) or production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid).Type: ApplicationFiled: September 2, 2010Publication date: December 6, 2012Applicant: DSM IP ASSETS B.V.Inventors: Harald Johan Ruijssenaars, Nick Johannes Petrus Wierckx, Frank Wouter Koopman, Adrianus Johannes Jozef Straathof, Johannes Hendrik De Winde
-
Publication number: 20110086395Abstract: An isolated microorganism is provided which is Cupriavidus basilensis strain HMF14 Deposit number DSM 22875, and its use in a process for the in-situ detoxification of lignocelluloses hydrolysate.Type: ApplicationFiled: September 2, 2010Publication date: April 14, 2011Inventors: Frank Wouter KOOPMAN, Harald Johan Ruijssenaars, Nick Johannes Petrus Wierckx, Johannes Hendrik De Winde